{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "CENTESSA PHARMACEUTICALS", "longName": "Centessa Pharmaceuticals plc", "messageBoardId": "finmb_704505677", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChangePercent": 0.0, "regularMarketPrice": 4.04, "marketState": "REGULAR", "firstTradeDateMilliseconds": 1623045600000, "priceHint": 4, "epsTrailingTwelveMonths": -2.19, "epsForward": -2.89, "epsCurrentYear": -2.22, "priceEpsCurrentYear": -1.8198198, "sharesOutstanding": 94961200, "bookValue": 3.544, "fiftyDayAverage": 3.5704, "fiftyDayAverageChange": 0.46959996, "fiftyDayAverageChangePercent": 0.13152587, "twoHundredDayAverage": 3.6145, "twoHundredDayAverageChange": 0.42549992, "twoHundredDayAverageChangePercent": 0.11772027, "marketCap": 402074112, "forwardPE": -1.3979238, "priceToBook": 1.1399549, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "prevName": "Centessa Pharmaceuticals Limited", "nameChangeDate": "2023-05-11", "averageAnalystRating": "1.7 - Buy", "tradeable": false, "cryptoTradeable": false, "regularMarketChange": 0.0, "regularMarketTime": 1683875702, "regularMarketDayHigh": 4.04, "regularMarketDayRange": "4.04 - 4.04", "regularMarketDayLow": 4.04, "regularMarketVolume": 45, "regularMarketPreviousClose": 4.04, "bid": 4.06, "ask": 4.44, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 4.04, "averageDailyVolume3Month": 0, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 1.3199999, "fiftyTwoWeekLowChangePercent": 0.48529407, "fiftyTwoWeekRange": "2.72 - 5.55", "fiftyTwoWeekHighChange": -1.5100002, "fiftyTwoWeekHighChangePercent": -0.2720721, "fiftyTwoWeekLow": 2.72, "fiftyTwoWeekHigh": 5.55, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "symbol": "260.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "1 Ashley Road", "address2": "3rd Floor", "city": "Altrincham", "zip": "WA14 2DT", "country": "United Kingdom", "phone": "44 203 9206789", "website": "https://www.centessa.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.", "fullTimeEmployees": 83, "companyOfficers": [{"maxAge": 1, "name": "Dr. Saurabh  Saha M.D., Ph.D.", "age": 45, "title": "CEO & Director", "yearBorn": 1977, "fiscalYear": 2022, "totalPay": {"raw": 957672, "fmt": "957.67k", "longFmt": "957,672"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Gregory M. Weinhoff M.B.A., M.D., MBA", "age": 51, "title": "Principal Accounting Officer & CFO", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 655004, "fmt": "655k", "longFmt": "655,004"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. David M. Chao Ph.D.", "age": 54, "title": "Chief Admin. Officer", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 655004, "fmt": "655k", "longFmt": "655,004"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Kristen K. Sheppard Esq., J.D.", "title": "Sr. VP of Investor Relations & Corp. Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Iqbal J. Hussain L.L.B.", "age": 41, "title": "Gen. Counsel, Chief Compliance Officer & Corp. Sec.", "yearBorn": 1981, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Karen M. Anderson", "age": 55, "title": "Chief People Officer", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Antoine  Yver M.D., M.Sc., MSc", "age": 64, "title": "Exec. VP & Chairman of Devel.", "yearBorn": 1958, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Tia L. Bush", "age": 51, "title": "Chief Quality Officer", "yearBorn": 1971, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. David John Grainger Ph.D.", "age": 53, "title": "Chief Innovation Officer", "yearBorn": 1969, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Harris L. Rotman Ph.D.", "title": "Sr. VP of Regulatory Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}